Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsy

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Sentinel lymph node biopsy, a minimally invasive procedure for staging patients with breast cancer, is a rapidly evolving technique in breast surgery. In response, a task force convened by the American Society of Breast Surgeons has issued a

Sentinel lymph node biopsy, a minimally invasive procedure for staging patients with breast cancer, is a rapidly evolving technique in breast surgery. In response, a task force convened by the American Society of Breast Surgeons has issued a consensus statement on performance and utilization criteria for this technique.

This statement outlines performance criteria for surgeons utilizing sentinel lymph node biopsy, identifies patients who are ineligible for the procedure, and encourages surgeons to participate in national registries and clinical trials that have been established for breast cancer lymphatic mapping. Additional information and copies of the consensus statement are available from the society at (301) 362-1722.

Dr. Michael J. Edwards, associate professor of surgery, Division of Surgical Oncology, University of Louisville, headed the task force, which included Dr. Armando E. Giuliano, chief of surgical oncology, John Wayne Cancer Institute, Santa Monica, California; Dr. Douglas Reintgen, professor of surgery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida; and Dr. Lorraine Tafra, assistant professor of surgery, East Carolina University School of Medicine.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.